Retatrutide Medicinal

Bibliography

References: the complete retatrutide citation record used on this site

Every cited source, with DOI or PubMed URL, organized numerically.

Primary clinical trial studies

The peer-reviewed publications and registered trial results from which all quantitative claims on this site are drawn. DOIs and PubMed URLs are provided for each entry.

  1. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. ↗
  2. Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. Lancet. 2023;402(10401):529-544. ↗
  3. Li W, Zhou Q, Cong Z, et al. Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Cell Discovery. 2024;10:77. ↗
  4. Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400:1869-1881. ↗
  5. Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 2024;30:2037-2048. ↗
  6. Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K. Retatrutide — A Game Changer in Obesity Pharmacotherapy. Biomolecules. 2025;15:796. ↗
  7. Mechanisms of GLP-1 in Modulating Craving and Addiction: Neurobiological Insights. Med Sci (Basel). 2025. ↗
  8. Appetite, eating attitudes, and eating behaviours during treatment with retatrutide. Diabetes Obes Metab. 2025. ↗
  9. Jiang Y, et al. Why does GLP-1 agonist combined with GIP and/or GCG agonist have greater weight loss effect than GLP-1 agonist alone in obese adults without type 2 diabetes? Diabetes Obes Metab. 2025;27(3):1079-1095. ↗
  10. Goetz IA, et al. Perceived benefits of treatment for obesity with retatrutide: A qualitative study of patients in a phase 2 clinical trial. Obesity Pillars. 2025;16:100220. ↗
  11. Urva S, et al. The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying. Diabetes Obes Metab. 2023;25(9):2784-2788. ↗
  12. Pardali EC, et al. New Drugs on the Block: Dietary Management and Nutritional Considerations During the Use of Anti-Obesity Medication. Nutrients. 2026. ↗
  13. Briand F, et al. Retatrutide Shows Multiple Metabolic Benefits in Diet-Induced Obese MASH Mouse and Hamster Models. Obesity (Silver Spring). 2026. ↗
  14. NCT06383390 — Cardiovascular outcomes trial for retatrutide (TRIUMPH cardiovascular/CKD program). ClinicalTrials.gov. ↗
  15. Body composition substudy: retatrutide reduces lean body mass alongside fat mass in people with type 2 diabetes. Lancet Diabetes Endocrinol. 2025. ↗
  16. NCT05929066 — TRIUMPH Phase 3 active-comparator trial (retatrutide vs tirzepatide). NCT05931367 — TRIUMPH-3. NCT05882045 — TRANSCEND-CKD. ClinicalTrials.gov. ↗
  17. Laroche ML, et al. Dysesthesia associated with GLP-1 agonist therapies: data-mining analysis and literature review. Eur J Clin Pharmacol. 2026. ↗